Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Drug Name | Dinutuximab beta |
Trade Name | |
Synonyms | ch14.18/CHO|APN311|APN-311|APN 311|Qarziba |
Drug Descriptions |
Dinutuximab beta (ch14.18/CHO) is biosimilar of the anti-GD2 antibody Unituxin (dinutuximab) produced in CHO cells, with a different glycosylation pattern than dinutuximab, which potentially induces antibody-dependent and complement-dependent cytotoxicity against GD2-expressing tumor cells, and reduces liver metastasis (PMID: 30613134, PMID: 15950727). |
DrugClasses | |
CAS Registry Number | NA |
NCIT ID | NA |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Aldesleukin + Dinutuximab beta | Aldesleukin Dinutuximab beta | 0 | 1 |
Cyclophosphamide + Dinutuximab beta + Topotecan | Cyclophosphamide Dinutuximab beta Topotecan | 0 | 1 |
Dinutuximab beta | Dinutuximab beta | 0 | 2 |
Dinutuximab beta + Nivolumab | Dinutuximab beta Nivolumab | 0 | 1 |
Dinutuximab beta + Temozolomide | Dinutuximab beta Temozolomide | 0 | 1 |
Dinutuximab beta + Temozolomide + Topotecan | Dinutuximab beta Temozolomide Topotecan | 0 | 1 |